Format

Send to

Choose Destination
Int Urol Nephrol. 2018 Sep;50(9):1619-1626. doi: 10.1007/s11255-018-1938-2. Epub 2018 Jul 16.

Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.

Author information

1
Department of Urology, Municipal Hospital Rzeszow, 4 Rycerska Street, 35-241, Rzeszow, Poland.
2
Department of Biotechnology and Bioinformatics, Faculty of Chemistry, Rzeszow University of Technology, 6 Powstańców Warszawy Street, 35-503, Rzeszow, Poland. eciszkow@prz.edu.pl.
3
Department of Biotechnology and Bioinformatics, Faculty of Chemistry, Rzeszow University of Technology, 6 Powstańców Warszawy Street, 35-503, Rzeszow, Poland.

Abstract

PURPOSE:

Prostate cancer (PCa) is a common tumor disease in western countries and a leading cause of cancer-driven mortality in men. Current methods for prostate cancer detection, like prostate-specific antigen screening, lead to significant overtreatment. The purpose of the study was to analyze circulating microRNAs in serum as non-invasive biomarkers in patients with diagnosis of prostate cancer and healthy individuals.

METHODS:

This preliminary study included a population of 20 patients with mean age of 68.6 years and mean PSA of 21.3 ng/ml. Eight healthy patients were used as control. MiRNAs were quantified in the total RNA fraction extracted from serum and levels of five microRNAs (miR-106b, miR-141, miR-21, mir-34a, and miR-375) were quantified by RT-qPCR. Statistical analyses evaluated correlation between clinicopathological data and miRNAs expression levels.

RESULTS:

Relative expression ratios of miR-106b, miR-141-3p, miR-21, and miR-375 were significantly increased (1.8-,  1.9-, 2.4-, and 2.6-fold, respectively) in the PCa group compared to healthy control. Using receiver operating characteristics, the highest area under the curve equal to 0.906 was obtained for miR-357 and indicates a very good diagnostic properties of this biomarker. We found expression level of mir-34a not related with PCa.

CONCLUSIONS:

Our results support previous findings on the possibility of discriminating prostate cancer patients from healthy controls by detecting miRNA (miR-141-3p, miR-21, and miR-375). Further insights into miRNA abundance and characteristics are necessary to validate the panel of miRNA as surrogate markers in diagnosis of prostate cancer.

KEYWORDS:

Biomarkers; Diagnosis; MiRNA; Prostate cancer

PMID:
30014459
PMCID:
PMC6133127
DOI:
10.1007/s11255-018-1938-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center